Paul Timpson
Garvan Institute and The Kinghorn Cancer Centre, NSW, Australia

Paul completed his PhD with Prof Margaret Frame at the Beatson Institute for Cancer Research, UK in 2002 where he assessed the interplay between Src family kinases and the actin cytoskeleton during cancer cell invasion, focusing on the role of Rho family GTPases. He then moved to the Garvan Institute in 2003 to work with Professor Roger Daly investigating the role of the actin-binding protein cortactin in growth factor receptor trafficking in breast cancer and head and neck cancers.
Paul was awarded an AstraZeneca Postdoctoral Research Fellowship allowing him to return to the UK in 2007, to work with Professor Kurt Anderson in collaboration with AstraZeneca Advanced Technology Laboratories. This ongoing work has focused upon the development of novel multi-disciplinary live imaging techniques to investigate molecular dynamics of cancer cells in vivo.
Returning to Australia to establish a research group in November 2012 within the Cancer Program, Paul aims to understand pancreatic cancer in the context of the surrounding environment using cutting edge imaging technology. Pinpointing the molecular drivers of cancer progression and the environmental cues that cause resistance to current systemic therapy are the focus of his research.
Presentations this author is a contributor to:
Pinpointing and targeting novel drivers of pancreatic cancer progression and metastasis using TRAP-seq. (#149)
12:45 PM
Michael Trpceski
Lunch & Poster Viewing (Odd Numbers)
Investigating novel matrisomal targets in PC to reduce fibrosis and improve standard-of-care chemotherapy. (#155)
12:45 PM
Jessie Zhu
Lunch & Poster Viewing (Odd Numbers)
Inhibition of the NPY signalling axis as a novel therapeutic option in Pancreatic Cancer. (#38)
12:35 PM
Cecilia Chambers
Concurrent Session - Cancer Biology
Targeting subcellular JNK activity in pancreatic cancer (#107)
12:45 PM
Antonia L Cadell
Lunch & Poster Viewing (Odd Numbers)
Temporal proteomic profiling reveals Nidogen-2 as a new stromal co-target in pancreatic cancer (#138)
1:00 PM
Brooke Pereira
Lunch & Poster Viewing (Even Numbers)
Putting the brakes on CDK4/6 inhibitor resistance in estrogen receptor positive breast cancers by harnessing the potential of CDK1 inhibition (#35)
12:05 PM
Sarah Alexandrou
Concurrent Session - Cancer Biology
SPEAR: A Phase 2, Open-label, Single-arm Monotherapy Trial of Sulfasalazine in Pancreatic Adenocarcinoma – Trial in Progress (#321)
12:45 PM
Omali Pitiyarachchi
Lunch & Poster Viewing (Odd Numbers)